WALTHAM, Mass., Aug. 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (AMEX:ILI) today announced that it will release its second quarter financial results on Thursday, August 9 after the market closes. The Company's management will host the conference call at 4:30 PM EDT to review Interleukin's 2007 second quarter financial results and provide management updates.

Conference Call Details

To access the live call on August 9, 2007 at 4:30 PM EDT, dial (800) 257- 3401 (domestic) or (303) 262-2005 (international). The call will also be available live via webcast at www.ilgenetics.com.

Replay access of the teleconference will be available for two weeks following the call by calling (800) 405-2236 (domestic) or (303) 590-3000 (international). The passcode for the replay is 11095100. The webcast will be archived following the call at www.ilgenetics.com.

About Interleukin

Interleukin Genetics, Inc. (AMEX:ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals, including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit www.ilgenetics.com.

Source: Interleukin Genetics, Inc.